Compare RGNX & ETO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGNX | ETO |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.6M | 493.0M |
| IPO Year | 2015 | 2004 |
| Metric | RGNX | ETO |
|---|---|---|
| Price | $11.90 | $30.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $28.75 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 36.6K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,393,000.00 | N/A |
| Revenue This Year | $51.21 | N/A |
| Revenue Next Year | $19.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 126.48 | N/A |
| 52 Week Low | $5.46 | $25.68 |
| 52 Week High | $16.19 | $31.26 |
| Indicator | RGNX | ETO |
|---|---|---|
| Relative Strength Index (RSI) | 79.66 | 57.08 |
| Support Level | $10.75 | $29.47 |
| Resistance Level | $12.05 | $30.84 |
| Average True Range (ATR) | 0.87 | 0.58 |
| MACD | 0.57 | 0.00 |
| Stochastic Oscillator | 96.16 | 85.16 |
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Eaton Vance Tax-advtgd Global Divid Oppo is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. The portfolio of investments consists of capital markets, chemicals, diversified, beverages, banks, electric utilities, oil, gas, and consumable fuels, personal products, and other areas.